ATC codes:
J01EE01
EMLc
Indication
Pneumocystosis
ICD11 code:
1F2G.Z
INN
Sulfamethoxazole + trimethoprim
Medicine type
Chemical agent
Antibiotic groups
List type
Core
(EML)
(EMLc)
(EMLc)
Formulations
Parenteral > General injections > IV:
80 mg + 16 mg per mL in 5 mL ampoule ;
80 mg + 16 mg per mL in 10 mL ampoule
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid (EMLc)
Oral > Solid: 100 mg + 20 mg tablet (EMLc) ; 400 mg + 80 mg tablet (EMLc) ; 800 mg + 160 mg tablet
Oral > Solid > dispersible tablet: 100 mg + 20 mg (EMLc)
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid (EMLc)
Oral > Solid: 100 mg + 20 mg tablet (EMLc) ; 400 mg + 80 mg tablet (EMLc) ; 800 mg + 160 mg tablet
Oral > Solid > dispersible tablet: 100 mg + 20 mg (EMLc)
EML status history
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength formulation of sulfamethoxazole + trimethoprim (dispersible tablet 100 mg + 20 mg) on the EMLc.